These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 10955351)

  • 1. Leukocytoclastic vasculitis due to etanercept.
    Galaria NA; Werth VP; Schumacher HR
    J Rheumatol; 2000 Aug; 27(8):2041-4. PubMed ID: 10955351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis.
    Clemente RE
    Scand J Rheumatol; 2007; 36(3):244-5; author reply 245. PubMed ID: 17657687
    [No Abstract]   [Full Text] [Related]  

  • 3. Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis.
    Martínez-Taboada VM; Val-Bernal JF; Pesquera LC; Fernández-Llanio NE; Esteban JM; Blanco R; Alonso-Bartolome P; Gonzalez-Vela C; Rodríguez-Valverde V
    Scand J Rheumatol; 2006; 35(4):322-3. PubMed ID: 16882599
    [No Abstract]   [Full Text] [Related]  

  • 4. Henoch-Schönlein purpura after etanercept therapy for psoriasis.
    Lee A; Kasama R; Evangelisto A; Elfenbein B; Falasca G
    J Clin Rheumatol; 2006 Oct; 12(5):249-51. PubMed ID: 17023811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein.
    Zeltser R; Valle L; Tanck C; Holyst MM; Ritchlin C; Gaspari AA
    Arch Dermatol; 2001 Jul; 137(7):893-9. PubMed ID: 11453808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.
    Mohan N; Edwards ET; Cupps TR; Slifman N; Lee JH; Siegel JN; Braun MM
    J Rheumatol; 2004 Oct; 31(10):1955-8. PubMed ID: 15468359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases.
    Fujikawa K; Kawakami A; Hayashi T; Iwamoto N; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Arima K; Kamachi M; Yamasaki S; Nakamura H; Ida H; Origuchi T; Eguchi K
    Mod Rheumatol; 2010 Feb; 20(1):86-9. PubMed ID: 19812889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digital vasculitis with eosinophilia possibly associated with etanercept therapy.
    Nakahigashi K; Egawa G; Miyachi Y; Kabashima K
    Acta Derm Venereol; 2014 Mar; 94(2):239-40. PubMed ID: 23824408
    [No Abstract]   [Full Text] [Related]  

  • 9. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.
    Mor A; Bingham CO; Barisoni L; Lydon E; Belmont HM
    J Rheumatol; 2005 Apr; 32(4):740-3. PubMed ID: 15801034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angio-oedema in a patient treated with etanercept for rheumatoid arthritis.
    Sendur OF; Turan Y; Berkit IK; Tastaban E
    Basic Clin Pharmacol Toxicol; 2009 Jun; 104(6):488-90. PubMed ID: 19371261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept Immunex.
    Yung RL
    Curr Opin Investig Drugs; 2001 Feb; 2(2):216-21. PubMed ID: 11816834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed multiple injection site reaction in a rheumatoid arthritis patient treated with etanercept.
    Rajakulendran S; Deighton C
    Rheumatology (Oxford); 2004 Dec; 43(12):1588-9. PubMed ID: 15564639
    [No Abstract]   [Full Text] [Related]  

  • 13. Leukocytoclastic vasculitis induced by low-dose methotrexate: in vitro evidence for an immunologic mechanism.
    Halevy S; Giryes H; Avinoach I; Livni E; Sukenik S
    J Eur Acad Dermatol Venereol; 1998 Jan; 10(1):81-5. PubMed ID: 9552765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis.
    Carlson E; Rothfield N
    Arthritis Rheum; 2003 Apr; 48(4):1165-6; author reply 1166. PubMed ID: 12687569
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.
    Genovese MC; Cohen S; Moreland L; Lium D; Robbins S; Newmark R; Bekker P;
    Arthritis Rheum; 2004 May; 50(5):1412-9. PubMed ID: 15146410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating leukocytoclastic vasculitis associated with etanercept therapy. Is it necessary to stop etanercept?
    Juan A; Ribas B; Nadal C; Ros I
    J Rheumatol; 2005 Oct; 32(10):2061; author reply 2061-2. PubMed ID: 16206372
    [No Abstract]   [Full Text] [Related]  

  • 17. Rituximab-induced vasculitis: A case report and review of the medical published work.
    Kim MJ; Kim HO; Kim HY; Park YM
    J Dermatol; 2009 May; 36(5):284-7. PubMed ID: 19382999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy.
    Smith KJ; Skelton HG
    J Am Acad Dermatol; 2001 Dec; 45(6):953-6. PubMed ID: 11712048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis.
    O'Dell JR; Petersen K; Leff R; Palmer W; Schned E; Blakely K; Haire C; Fernandez A
    J Rheumatol; 2006 Feb; 33(2):213-8. PubMed ID: 16358366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.
    Lee JH; Slifman NR; Gershon SK; Edwards ET; Schwieterman WD; Siegel JN; Wise RP; Brown SL; Udall JN; Braun MM
    Arthritis Rheum; 2002 Oct; 46(10):2565-70. PubMed ID: 12384912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.